Share your insights

Help us by sharing what content you've recieved in your exams


Trichomonas Vaginalis

Background knowledge 🧠

Definition

  • Trichomonas vaginalis is a protozoan parasite that causes trichomoniasis, a sexually transmitted infection (STI).
  • It primarily affects the urogenital tract.
  • Most common in women but can also affect men.

Epidemiology

  • Worldwide, trichomoniasis is one of the most common non-viral STIs.
  • More prevalent in sexually active women aged 16-35 years.
  • Higher prevalence in resource-limited settings.
  • UK prevalence: Approximately 0.2% among women in reproductive age.
  • Increased risk in individuals with multiple sexual partners.

Aetiology and Pathophysiology

  • Caused by the anaerobic protozoan Trichomonas vaginalis.
  • Transmission primarily through sexual contact.
  • In women, infects the vagina, urethra, and paraurethral glands.
  • In men, primarily affects the urethra, but may also infect the prostate.
  • Disruption of vaginal flora (e.g., reduction of Lactobacillus) may increase susceptibility.
  • Can survive in the genital tract for months to years if untreated.

Clinical Features 🌑️

Symptoms

  • In women: Frothy, yellow-greenΒ vaginal dischargeΒ with an unpleasant odour.
  • Vaginal itching and irritation.
  • Dysuria and urinary frequency.
  • Symptoms may worsen during menstruation.
  • In men:Β Often asymptomatic but can include urethral discharge and dysuria.
  • Up to 50% of women and 90% of menΒ may be asymptomatic.

Signs

  • Erythema and oedema of the vulva and vagina.
  • Strawberry cervix (punctate hemorrhages on the cervix) in approximately 2% of cases.
  • Vaginal pH typically >4.5.
  • Thin, frothy discharge visible on speculum examination.
  • May have associated cervicitis.

Investigations πŸ§ͺ

Tests

  • Microscopy of vaginal or urethral swab showing motile trichomonads (flagellated protozoa).
  • Culture: Sensitivity approaches 95% but results may take 3-7 days.
  • NAAT (Nucleic Acid Amplification Test) is the gold standard due to high sensitivity and specificity.
  • Wet mount microscopy may be done in clinics but has lower sensitivity.
  • Consider screening for other STIs, such as Chlamydia and Gonorrhea.

Management πŸ₯Ό

Management

  • First-line treatment: Metronidazole 400-500 mgΒ orally twice daily for 5-7 days.
  • Alternative: Single dose of 2g metronidazole (increased side effects).
  • Treat sexual partners simultaneously to prevent reinfection.
  • Advise abstaining from sexual activityΒ until treatment completion and symptoms resolve.
  • Pregnancy: Metronidazole is considered safe but discuss risks/benefits.
  • Consider alternative antibiotics if metronidazole is contraindicated.
  • Re-test in 3 months for recurrent infections.

Complications

  • Increased risk of HIV transmission and acquisition.
  • Pelvic inflammatory disease (PID) in women.
  • In pregnant women: Preterm birth, low birth weight, and postpartum endometritis.
  • Prostatitis and urethritis in men.
  • Potential for long-term genitourinary complications if untreated.

Prognosis

  • Excellent with appropriate treatment.
  • High cure rates with metronidazole therapy.
  • Risk of recurrence if sexual partners are not treated.
  • Reinfection is common due to poor partner compliance or reinfection.
  • Routine follow-up recommended to ensure clearance.

Key Points

  • Trichomoniasis is a common and treatable STI caused by Trichomonas vaginalis.
  • Symptomatic women often present with frothy, malodorous discharge.
  • Men are frequently asymptomatic but can contribute to transmission.
  • NAAT is the preferred diagnostic method due to high sensitivity.
  • Metronidazole is the treatment of choice; sexual partners must be treated to prevent reinfection.
  • Complications include increased risk of HIV transmission and adverse pregnancy outcomes.
  • Routine follow-up is essential to ensure treatment efficacy and prevent recurrence.

No comments yet πŸ˜‰

Leave a Reply